Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
about
Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablationCardiovascular gene therapy for myocardial infarctionHERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cellsc-Jun N-terminal kinase activation contributes to reduced connexin43 and development of atrial arrhythmias.Pro-arrhythmogenic effects of atrial fibrillation-induced electrical remodelling: insights from the three-dimensional virtual human atriaConnexin 43 a check-point component of cell proliferation implicated in a wide range of human testis diseases.Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation.Atrial fibrillation complicated by heart failure induces distinct remodeling of calcium cycling proteinsBiological Heart Rate Reduction Through Genetic Suppression of Gα(s) Protein in the Sinoatrial Node.In silico assessment of genetic variation in KCNA5 reveals multiple mechanisms of human atrial arrhythmogenesisRegulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.The Use of Gene Therapy for Ablation of Atrial Fibrillation.Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system.Biological Therapies for Atrial Fibrillation: Ready for Prime Time?Gene therapy to treat cardiovascular disease.Expression of connexin 43, ion channels and Ca2+-handling proteins in rat pulmonary vein cardiomyocytes.Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.Cardiac gene therapy in large animals: bridge from bench to bedside.Novel molecular targets for atrial fibrillation therapy.Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium.Cardiac to cancer: connecting connexins to clinical opportunity.Atrial fibrillation-linked GJA5/connexin40 mutants impaired gap junctions via different mechanisms.Mechanisms linking connexin mutations to human diseases.MicroRNAs and atrial fibrillation: mechanisms and translational potential.Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation.Gene therapy to treat cardiac arrhythmias.microRNA expression changes after atrial fibrillation catheter ablation.Connexin Remodeling Contributes to Atrial Fibrillation.Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.Improving Atrial Fibrillation Therapy: Is There a Gene for That?Role of atrial tissue remodeling on rotor dynamics: an in vitro study.Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue?Demystifying rotors and their place in clinical translation of atrial fibrillation mechanisms.Gene Therapy for Atrial Fibrillation in Heart Failure.Current state of the art for cardiac arrhythmia gene therapy.Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate.Gene Therapy for Cardiac Arrhythmias.Connexin 43 is involved in the sympathetic atrial fibrillation in canine and canine atrial myocytes.TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control.Association of atrial fibrillation with gene polymorphisms of connexin 40 and angiotensin II receptor type 1 in Chongming adults of Shanghai.
P2860
Q26864767-904654A4-2259-4D1A-BBBA-91AB3126B401Q27014770-50EB2535-E247-4FF4-9669-2B441B699110Q28539628-10AF690A-6BCA-444E-A3DC-27B1BB420C27Q30535024-F2154E01-840D-483E-911E-AE110E060DFBQ30545769-F6867DD0-2F20-421D-8E67-390A72E3832DQ34295662-4845780E-B989-419A-B748-A4420D42EDCAQ34307746-ED6D5D50-4596-43BA-ADE0-954C2C65B8EBQ35180988-31B75697-C603-4CFA-B26C-76AFDF5C323CQ36366373-4B8D333F-8FC7-4105-A15C-7670F539136DQ36407327-7B9E16F3-B2D0-463F-A50F-1D61F1D077BCQ36446536-4B645544-BBFB-4A7A-9A66-582F9A451AF9Q36458906-E89A07CC-7B19-420B-93C5-7CAE932FAA1AQ36713691-09480BF4-B186-4DE6-8BC9-7E5B35AA270EQ36934761-BC1A29C7-B5ED-4E0A-9DB1-B7C897FAD106Q37310450-E13A6018-1B6B-4622-ADD1-E8DCD51842F9Q37406549-53E1A009-7623-4B1F-8506-32425BCFF5C3Q37602866-110B595D-5359-44C7-9E6D-6CA199E3D62BQ37981008-F5B700FC-070A-4F4B-A723-7593D0B7C089Q37998312-AEC6AD85-39BB-4AD6-B7C3-73723BD205BAQ38132253-2F7DF3C0-9BED-4701-8BD6-321E64937C00Q38194340-25CFA8E3-43C9-4C06-845C-BD09A79A2876Q38198336-36384BEF-7638-48C7-9432-AF878B4B514BQ38268356-5E082D03-AC4D-4401-939D-C3C5808AF1FDQ38271026-F974DF64-AC88-4B87-92A7-20C94B271A9CQ38435600-0CA3A9A3-7DB3-4310-9EFB-82F45A157C99Q38444909-88EA4D2A-895A-4F4F-B516-34C89F0A5302Q38629524-BBA3551D-2AB5-430C-AD8F-97866C383C6CQ38790389-127C3284-E34C-4F33-B694-B4559072D739Q38822819-B40D1C8F-8ED8-4B22-8681-073F7262D698Q38828102-C1785E28-85AD-401E-A004-DDEB9E08C144Q38832340-C3E4C2C6-1759-45E3-AF0C-CEDB68DCC32FQ38846401-C2041DAD-3D35-48EA-9630-601623132BB5Q39223917-EB9A0376-690A-43C6-B13E-F721C0A89A38Q39332399-F14EB04A-3DEB-4018-8739-FADBED4A0FC0Q39392472-D2F29B60-D72C-47B7-9185-FFC90DF8308EQ39741408-AEF036BF-2C76-4D59-AE05-E271075E8CD6Q39815208-40D76768-DACE-4FEF-BE94-3E8471D829B1Q41026703-2D9C0AB9-7810-454A-B6D1-A501081A256BQ42008383-49F05CA1-014D-4BC7-A372-30841AE34DF0Q43183347-409A3C0F-3A4C-4384-91C4-7DE1777628E1
P2860
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@en
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@nl
type
label
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@en
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@nl
prefLabel
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@en
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@nl
P2093
P2860
P356
P1476
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
@en
P2093
Alexander Bauer
Dierk Thomas
Frederik Voss
Hugo A Katus
Kamilla Kelemen
Kerstin Trappe
Martin Koch
Olympia Bikou
Patrick Lugenbiel
Radim Soucek
P2860
P304
P356
10.1093/CVR/CVR209
P577
2011-07-28T00:00:00Z